Cell Therapy for Autoimmune Disease Insights & News

Learn More About the Cell Therapy for Autoimmune Disease Summit in 2026

The 4th Cell Therapy for Autoimmune Disease Summit brings together the companies, researchers, and clinical leaders working to define the future of immune reset therapies. Explore the articles below to gain insight into the latest developments across CAR-T, CAR-NK, Treg, MSC, allogeneic, autologous, and in vivo cell therapy approaches, alongside the practical challenges shaping the field. These are the discussions helping determine how autoimmune cell therapies can evolve from promising clinical programs into broadly accessible treatments for patients.

Autologous vs Allogeneic vs In Vivo Cell Therapy

Explore the advantages and challenges of autologous, allogeneic, and in vivo cell therapy approaches, and discover which modality is best positioned to advance the treatment of autoimmune diseases.

How Immune Reset is Shaping Autoimmune Treatment

Discover how immune reset strategies are reshaping autoimmune disease treatment through the potential of cell therapies to restore long-term immune tolerance.

Moving Beyond CD19 in Autoimmune Cell Therapy

Explore why developers are evaluating targets beyond CD19 and how new approaches to B-cell depletion, immune regulation, and precision targeting could shape the next generation of therapies.